Myla Lai-Goldman
Venture Partner @ Hatteras Venture Partners
South Burlington, United States
Myla Lai-Goldman is a Co-Founder and Chair at GeneCentric Therapeutics and a Venture Partner at Hatteras Venture Partners. Myla was an Executive VP, CMO, and CSO at Labcorp. She attended Columbia University Vagelos College of Physicians and Surgeons and the University of Pennsylvania,
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Myla Lai-Goldman invests in
Stages Myla Lai-Goldman invests in
Countries Myla Lai-Goldman invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Medical Device 1 (100%)
- Machine Learning 1 (100%)
- Artificial Intelligence 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biocogniv
|
More than a decade since the HITECH Act established a timeline for EHR adoption, US hospitals today find themselves generating more clinical and administrative data on any given day than previously thought possible. Yet clinical operations are still based on subjective decision-making and traditional processes that ignore not only the raw data, butalso the valuable efficiency improvements that can be automatically derived from them.Biocogniv picks up where the EHR transformation left off and introduces real-time intelligence on top of this vast backdrop of data, to improve the quality, cost, and ultimately access to care in US health systems. | $6M / Seed / Mar 16, 2022 |
Co-Investors
Breyer Capital
2 deals together
1984 Ventures
1 deal together
AltaIR Capital
1 deal together
Hula
1 deal together
Inflect Health
1 deal together
Promus Ventures
1 deal together
About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Hatteras Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Douglas Reed
General Partner
|
|||
Jeff Terrell
General Partner
|
|||
|
Myla Lai-Goldman
Venture Partner
|
|||
Christy L. Shaffer
General Partner
|
|||
Clay B. Thorp
General Partner and Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Myla Lai-Goldman invest in?
Myla Lai-Goldman invests primarily in Health Care, Medical Device and Machine Learning startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Myla Lai-Goldman last invest?
The most recent investment recorded for Myla Lai-Goldman closed in Mar 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
